- In April 2023, Siemens Healthineers launched an enhanced version of its cystatin C assay kit designed for improved accuracy and compatibility with high-throughput chemistry analyzers. This development supports the growing demand for reliable renal biomarkers in early-stage kidney disease diagnosis and underscores the company’s commitment to innovation in laboratory diagnostics. The new assay enables faster processing and higher precision, making it suitable for both hospital and reference laboratory use
- In March 2023, Gentian Diagnostics ASA expanded the availability of its CE-marked cystatin C immunoassay across additional global markets. The assay, optimized for automated platforms, aims to meet the increasing clinical need for standardized renal function testing. Gentian’s strategic expansion highlights its focus on addressing global health challenges through biomarker innovation and boosting access to high-quality diagnostic tools in emerging and developed regions
- In March 2023, Roche Diagnostics collaborated with multiple academic institutions to support ongoing research into the use of cystatin C as a predictive biomarker for cardiovascular and renal complications in diabetic patients. The partnership is part of Roche’s broader strategy to advance personalized medicine and improve outcomes through data-driven diagnostics, emphasizing the clinical versatility of cystatin C beyond traditional kidney function testing
- In February 2023, BioVendor Group introduced a fully automated ELISA processing system tailored for renal biomarkers, including cystatin C. The system is designed to streamline workflow in clinical laboratories by minimizing manual intervention and enhancing result consistency. This innovation reflects BioVendor’s ongoing efforts to optimize diagnostic efficiency and address the operational challenges faced by modern laboratories
- In January 2023, Randox Laboratories launched a new range of cystatin C control and calibration solutions aimed at ensuring assay accuracy and compliance with international quality standards. These products are intended to support clinical labs in maintaining the precision of cystatin C testing, which is increasingly being adopted for early detection of kidney dysfunction. The launch highlights Randox’s role in strengthening the diagnostic ecosystem through reliable quality assurance solutions
